Nasal Drug Delivery Market Revenue to Cross USD 26.8 Billion by 2035 | Roots Analysis

Published: February 2024

According to a recently published report by Roots Analysis, the growing preferences for precision medicine and target-specific therapies have increased the demand for RNAi therapeutics and technology.

Global Nasal Drug Delivery Market Overview

The global nasal drug delivery market is anticipated to grow at a CAGR of 18.3%  from 2023-2035, reaching USD 26.8 billion by 2035.

RNAi therapeutics refers to the novel class of innovative drugs that harness the RNA interference (RNAi) property of genes for the regulation of the expression system naturally inside the cells. In the past few years, RNAi therapies have garnered significant attention owing to their ability to treat a broad array of diseases, including metabolic diseases, chronic diseases, and cancer. It is interesting to note here that, in 2018, ONPATTRO® became the first RNAi-based therapy to receive approval from the FDA to treat patients suffering from chronic diseases. Since then, three consecutive RNAi-based therapies, namely, GIVLAARI® (November 2019), LEQVIO® (October 2020), and OXLUMO™ (November 2020), have received approval from the FDA. Notably, more than 200 RNAi therapeutics are currently being evaluated across different clinical trials for the treatment of a broad array of disease indications. Currently, several industrial players are increasing their research efforts for the development of RNA interference technology aiming to enhance efficacy and reduce effector molecule concentrations based on the anti-sense approach. Driven by the ongoing research, it is estimated that the market will grow during the forecast period.

The 421-page report contains a detailed Table of Content on "Nasal Drug Delivery Market," Key Therapeutic Areas, Route of Administration, Leading Industry Players, Type of RNAi Molecule and Global Forecasts, 2023-2035” here:

Market Drivers

RNAi technology enables the development of precision medicine by selectively silencing specific genes associated with particular diseases. Further, RNAi technology also holds significant potential in the treatment of genetic disorders owing to its ability to modulate the disease-causing gene. The RNAi therapeutic and technology market is further driven by the ongoing research on this gene silencing mechanism as an essential tool for the treatment of cancer. The growing usage of RNAi technology in the development of antiviral therapies becomes a primary driver propelling the growth in the RNAi therapeutic and technology market.

Market Restraints

Delivery challenges and off-target effects are the major market restraints that impede its growth. The introduction of RNA molecules to particular cells may trigger an immune response that can reduce the effectiveness of the RNAi therapeutics. Furthermore, large-scale production of RNAi therapeutics can be challenging for companies. Navigating the complex regulatory pathway to demonstrate the safety and efficacy of RNAi therapeutics can be difficult for companies.

Growth Factors

The ongoing progress of RNAi therapeutics in clinical trials and rising approval from the regulatory authorities are the key growth factors driving the market. Researchers in this field are continually exploring the new therapeutic applications of RNAi technology beyond conventional therapeutics to treat a broad range of diseases. Additionally, the ongoing advancement in the delivery system to enhance the therapeutic efficiency of RNAi therapeutics has become another essential growth factor that will drive the market in the future.

Nasal Drug Delivery Market Segments

Based on the Type of Indication, the Nasal Drug Delivery Market is Segmented into Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome.

  • The dry eye syndrome will dominate the market during the forecast period and is poised to capture 60% of the revenue share by 2035.
  • Nasal Polyps will grow during the forecast period at a higher CAGR of 28.3%.

Based on the Type of Molecules, the Nasal Drug Delivery Market is Segmented into Biologics and Small Molecules.

  • Based on the type of molecules, the Nasal Drug Delivery Market is dominated by small molecules, capturing 95% of the market share by 2035.
  • In the long run, biologics will grow at a higher compounded annual growth rate (CAGR) of 22% during the forecast period.

Based on the Leading Players, the Nasal Drug Delivery Market is Captured by Aptar Pharma, Biomed Industries, Biohaven Pharmaceuticals, Impel NeuroPharma, Mystic Pharmaceuticals, Nemera, Optinose, Oyster Point Pharma, Teleflex, and Zeteo Medical.

  • Oyster Point Pharma will dominate the market during the forecast period and is poised to capture 60% of overall revenue share by 2035. 
  • Impel NeuroPharma is likely to show the highest potential to grow during the forecast period at a CAGR of 41%.

Based on the Key Geographical Insight, The Nasal Drug Delivery Market is Segmented into North America, Europe, Asia-Pacific and rest of the world.

  • North America will dominate the nasal drug delivery market and is anticipated to hold a significant share of (80%) by 2035.
  • In Asia-Pacific, the market will grow at a higher CAGR value of 24% during the forecast period.

Key Companies Profiled

The Nasal Drug Delivery Market report also includes detailed profiles of key players (listed below) that offer biosensor solutions for drug discovery.

  • Aptar Pharma
  • Nemera
  • Teleflex
  • Mystic Pharmaceuticals
  • Zeteo Medical

You Can Download Free Sample PDF Copy of This Report At:

Don’t Miss Out on Other Interesting Titles:

  1. Viral Vectors Manufacturing Market
  2. Wearable Injectors Market 
  3. Intracellular Drug Delivery Market
  4. Targeted Drug Delivery System Market
  5. Long Acting Drug Delivery Market

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: or


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry